首页> 美国卫生研究院文献>Frontiers in Physiology >A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
【2h】

A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System

机译:一个详细的基于生理的模型来模拟依那普利在循环内分泌肾素-血管紧张素-醛固酮系统上的药代动力学和激素药效学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathogenesis of cardiovascular disorders including hypertension and is one of the most important targets for drugs. A whole body physiologically based pharmacokinetic (wb PBPK) model integrating this hormone circulation system and its inhibition can be used to explore the influence of drugs that interfere with this system, and thus to improve the understanding of interactions between drugs and the target system. In this study, we describe the development of a mechanistic RAAS model and exemplify drug action by a simulation of enalapril administration. Enalapril and its metabolite enalaprilat are potent inhibitors of the angiotensin-converting-enzyme (ACE). To this end, a coupled dynamic parent-metabolite PBPK model was developed and linked with the RAAS model that consists of seven coupled PBPK models for aldosterone, ACE, angiotensin 1, angiotensin 2, angiotensin 2 receptor type 1, renin, and prorenin. The results indicate that the model represents the interactions in the RAAS in response to the pharmacokinetics (PK) and pharmacodynamics (PD) of enalapril and enalaprilat in an accurate manner. The full set of RAAS-hormone profiles and interactions are consistently described at pre- and post-administration steady state as well as during their dynamic transition and show a good agreement with literature data. The model allows a simultaneous representation of the parent-metabolite conversion to the active form as well as the effect of the drug on the hormone levels, offering a detailed mechanistic insight into the hormone cascade and its inhibition. This model constitutes a first major step to establish a PBPK-PD-model including the PK and the mode of action (MoA) of a drug acting on a dynamic RAAS that can be further used to link to clinical endpoints such as blood pressure.
机译:肾素-血管紧张素-醛固酮系统(RAAS)在包括高血压在内的心血管疾病的发病机理中起着关键作用,并且是药物最重要的靶标之一。结合该激素循环系统及其抑制作用的基于全身生理学的药代动力学(wb PBPK)模型可用于探索药物干扰此系统的影响,从而增进对药物与靶标系统之间相互作用的了解。在这项研究中,我们描述了机械RAAS模型的开发,并通过模拟依那普利的给药来举例说明药物作用。依那普利及其代谢物依那普利拉是血管紧张素转换酶(ACE)的有效抑制剂。为此,开发了耦合的动态母体代谢物PBPK模型,并将其与RAAS模型链接,该模型由醛固酮,ACE,血管紧张素1,血管紧张素2,血管紧张素2受体类型1,肾素和肾上腺素的七个耦合PBPK模型组成。结果表明,该模型以准确的方式代表了对依那普利和依那普利拉的药代动力学(PK)和药效学(PD)响应的RAAS中的相互作用。在给药前和给药后的稳定状态以及它们的动态过渡过程中,一贯地描述了完整的RAAS激素概况和相互作用,并与文献数据很好地吻合。该模型可以同时表示母体-代谢物向活性形式的转化以及药物对激素水平的影响,从而提供了有关激素级联反应及其抑制作用的详细机理信息。该模型构成了建立PBPK-PD模型的第一步,该模型包括PK和作用于动态RAAS的药物的作用方式(MoA),可进一步用于链接至临床终点(例如血压)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号